CMN Weekly (17 September2021)

Some of the best links we picked up around the internet

By: Gorm Palmgren - Sep. 17, 2021

Top picks

  • Several researchers have attempted to use CRISPR to correct dystrophin mutations in Duchenne muscular dystrophy (DMD). Still, when cultured human cells are used for correction, it can be challenging to evaluate the physiological effect of the modification. To this end, British researchers have developed a system for optogenetic modelling of patient-derived neuromuscular circuits with CRISPR and pharmacological corrections in compartmentalised microdevices. Based on their results, the researchers suggest that targeting pathways in neuromuscular connectivity may be an effective therapeutic strategy for treating DMD regardless of the types of mutations.
  • Researchers from the Netherlands describe an in vitro diagnostic tool that uses CRISPR-Cas12a to identify and quantify single CpG methylation sites. According to the method, the target DNA is first digested with a methylation-sensitive restriction enzyme that cuts non-methylated sequences influencing the R-loop formation between crRNA and target DNA. Thus, the method allows for the deduction of the methylation position from the cleavage activity and opens the possibility to easily and rapidly study single CpG methylation sites for disease detection.

Research

Industry

COVID-19

  • Canadian researchers have developed a one-tube assay for the detection of viral RNA. The method combines reverse transcription, recombinase polymerase amplification, and CRISPR-Cas12a nuclease reactions under isothermal conditions at 40 °C. Detection of 200 or more copies of the S gene sequence of SARS-CoV-2 RNA within 5–30 min was demonstrated.

Reviews

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

CLINICAL TRIALS
Acute Myeloid Leukemia, AML, (NCT05066165)
Sponsors:
Intellia Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
CAR T for CD19+ hematological cancers, (NCT05037669)
Sponsors:
University of Pennsylvania
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine